IMMIX BIOPHARMA, INC. (IMMX)

Import this data to Google Sheets with:

=jivedata("IMMX","financials")

Full statements spill as a table. For one cell: =jivedata("IMMX","Revenue") or =jivedata("IMMX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

IMMIX BIOPHARMA, INC.

IMMX • CIK 0001873835

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
General and Administrative Expense	$7,406.082	$11,381.978	$13,697.817	$20,191.268
Research and Development Expense	$8,735.031	$11,292.702	$16,258.598	$21,624.715
Operating Income (Loss)	$-16,141.113	$-22,674.68	$-29,956.415	$-41,815.983
Operating Expenses	$16,141.113	$22,674.68	$29,956.415	$41,815.983
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$-15,569.107	$-21,657.326	$-29,400.889	$-39,883.901
Income Tax Expense (Benefit)	$26.415	$41.037	$37.724	$33.31
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-15,595.522	$-21,698.363	$-29,438.613	$-34,996.085
Net Income (Loss) Attributable to Noncontrolling Interest	$-169.474	$-84.987	$-84.987	$-84.987
Net Income (Loss) Attributable to Parent	$-15,426.048	$-21,613.376	$-29,438.613	$-39,917.211
Weighted Average Number of Shares Outstanding, Basic	17,341,146	28,285,637	32,965,706	62,714,668
Investment Income, Interest	$572.006	$1,017.354	$555.526	$1,932.082
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	$47.645	$-135.722	$61.216	$-5.79
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	—	$-21,749.098	$-29,377.397	$-39,863.523

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$17,509.791	$17,681.954	$93,928.566	$225,491.985
Short-term Investments	—	—	$6,480.86	$6,615.168
Assets	$19,925.16	$22,947.872	$104,840.341	$239,108.896
Income Taxes Receivable	$1,172.183	$1,974.37	$1,974.37	$0
Prepaid Expense and Other Assets, Current	$1,105.776	$541.51	$828.329	$1,682.918
Assets, Current	$19,787.75	$20,197.834	$101,237.755	$233,790.071
Other Assets, Noncurrent	—	$20.418	$20.418	$20.418
Deferred Costs, Noncurrent	$87.229	$87.229	$93.63	$164.723
Operating Lease, Right-of-Use Asset	—	$989.471	$966.917	$887.837
Property, Plant and Equipment, Net	$50.181	$1,740.149	$2,521.621	$2,358.428
Liabilities, Current	$3,721.783	$8,687.118	$10,110.546	$9,301.705
Operating Lease, Liability, Noncurrent	—	$1,009.551	$933.625	$890.638
Liabilities	$3,721.783	$9,696.669	$11,044.171	$10,192.343
Accounts Payable and Accrued Liabilities, Current	$3,721.783	$8,621.899	$9,971.207	$9,190.591
Operating Lease, Liability, Current	—	$65.219	$139.339	$111.114
Common Stock, Value, Issued	$2	$2.762	$5.301	$7.16
Additional Paid in Capital	$69,779.706	$88,374.131	$198,293.956	$354,997.609
Accumulated Other Comprehensive Income (Loss), Net of Tax	$134.666	$-1.056	$60.16	$118.72
Retained Earnings (Accumulated Deficit)	$-53,411.295	$-75,024.671	$-104,463.284	$-126,106.973
Treasury Stock, Common, Value	—	—	$99.963	$99.963
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$16,203.377	$13,251.203	$93,796.17	$228,916.553
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	200,000,000	200,000,000	200,000,000	200,000,000
Common Stock, Shares, Issued	19,994,719	27,612,383	53,023,466	71,608,042
Common Stock, Shares, Outstanding	19,922,356	27,540,020	52,951,103	71,535,679
Treasury Stock, Common, Shares	72,363	72,363	72,363	72,363

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-15,595.522	$-21,698.363	$-29,438.613	$-34,996.085
Net Cash Provided by (Used in) Operating Activities	$-11,371.438	$-14,595.102	$-23,930.304	$-38,498.081
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$33.092	$-3.622	$3.842	$-20.445
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$4,073.077	$172.163	$76,246.612	$213,854.04
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	$17,509.791	$17,681.964	$93,928.566	$157,257.628
Share-based Payment Arrangement, Noncash Expense	$2,565.708	$3,020.573	$2,441.875	$2,594.972
Payments to Acquire Property, Plant, and Equipment	$52.089	$1,177.68	$732.925	$591.111
Depreciation	$5.468	$32.941	$245.747	$331.67
Payments to Acquire Short-term Investments	—	—	$6,480.86	$6,480.86
Finance Lease, Right-of-Use Asset, Amortization	—	$82.447	$118.754	$155.466
Net Cash Provided by (Used in) Investing Activities	$-52.089	$-1,177.68	$-7,213.785	$-9,149.614
Payment of Financing and Stock Issuance Costs	$234.616	$234.616	$136.999	$136.999
Proceeds from Stock Options Exercised	$2.618	—	$6.342	$45.21
Proceeds from Issuance of Common Stock	$15,520.51	$15,946.078	$107,392.716	$247,010.678
Net Cash Provided by (Used in) Financing Activities	$15,463.512	$15,948.567	$107,386.859	$261,522.18
Interest Paid, Excluding Capitalized Interest, Operating Activities	$9.596	—	—	$9.596
Stock Issued	—	—	$0.026	$0.026
Increase (Decrease) in Income Taxes Receivable	$893.401	$971.527	$-2,059.507	$-55.202
Increase (Decrease) in Prepaid Expense and Other Assets	$-111.842	$-554.77	$286.729	$995.327
Increase (Decrease) in Other Current Assets	—	$20.418	$20.418	$20.418
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities	—	$4,401.623	$1,027.161	$-549.166
IncreaseDecreaseInOperatingLeaseLiability	—	$2.852	$-98.006	$-137.25

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("IMMX","financials")

Full statements spill as a table. For one cell: =jivedata("IMMX","Revenue") or =jivedata("IMMX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.